Practical efficacy
®
®
. 266, 15232 , . 210 6882100
3, 55133, , . 2310 422788
GR/FFT/0016/15(1)
: 10/2015-10/2016
1. Bleecker ER et al. JACI Parct 2014; 2:553-61 2.Boscia JA et al. Clin Ther. 2012; 34(8): 1655-66.e5 3. Relvar, 9/2015 4.Svedsater et al, Prim Care Resp
Med 2014; 24,14019 5. Woepse M et al. EAACI 2013, poster 1976
/ 210 6882100.
.
GlaxoSmithKline
, RELVAR® Ellipta®, 92/22g 184/22g.
Relvar® Ellipta® 12
"'"
2 ...
FEV1<70% ( )
3
.
: 184/22 mcg 92/22 mcg
3
: 92/22 mcg
3
To RELVAR® Ellipta®
ICS/LABA ( /
), 24
1,2
,
1,3
4,5
()
()
()
Relvar 92/22
35,92
31,25
49,50
Relvar 184/22
48,21
41,94
66,43
RELVAR PHARMACIES 21x28 indd 1
24/11/2015 2:50:12
124.